CDD0102 is primarily utilized in the field of pharmaceutical research as a potential therapeutic agent. It has shown promise in preclinical studies for its ability to modulate specific biological pathways, making it a candidate for the treatment of certain chronic diseases. Researchers are particularly interested in its application for targeting inflammatory conditions and metabolic disorders due to its unique mechanism of action. Additionally, CDD0102 is being explored for its potential in enhancing the efficacy of existing treatments when used in combination therapies. Its development is still in the experimental stages, with ongoing studies aimed at optimizing its pharmacokinetic properties and ensuring safety for potential clinical use.